Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Celsis Suing Over ADME Assay

By Drug Discovery Trends Editor | July 13, 2010

Celsis In Vitro, Inc. announced that it has filed a patent infringement lawsuit against Invitrogen Corporation and CellzDirect, Inc. in the United States District Court for the Northern District of Illinois in Chicago and has moved for a preliminary injunction.  Invitrogen, the parent of CellzDirect, is itself a wholly-owned subsidiary of Life Technologies of Carlsbad, California. The complaint alleges that certain processes and methods performed by CellzDirect associated with its in vitro drug testing services and its pooled cryopreserved epatocytes products infringe one or more claims of U.S. Patent No. 7,604,929 (the ‘929 patent).  The complaint also alleges that Invitrogen is selling these infringing products and services, as well as inducing infringement of the ‘929 patent, and seeks monetary damages and injunctive relief. 

Last month, Celsis IVT successfully reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. In a similar patent infringement lawsuit involving the ‘929 patent. Celsis is represented by Jordan Sigale and Adam Kelly of Loeb & Loeb LLP.

The ‘929 patent relates to processes and methods for producing cryopreserved hepatocytes.  In general, this technology combines hepatocytes from multiple donors to create large lots with targeted activity levels, the result of which is a product that speeds up decision making and reduces the time and cost of drug research. Since 2005, Celsis IVT has used this novel technology to create its unique LiverPool products for drug discovery research. Major pharmaceutical companies around the world have incorporated these LiverPool products into their standard research protocols.  Research conducted with LiverPool has confirmed its outstanding efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies. 

“Celsis believes that innovations are the lifeblood of the life sciences industry.  Advancements must be protected and respected if we are to further the cause of cost-effective drug discovery,” said Jay LeCoque, CEO of Celsis.  “We are extremely disappointed that we have been forced into this litigation, but the predatory pricing employed by Invitrogen and CellzDirect suggests a serious attempt to erode our patent-protected market position for the LiverPool product line.”  He added, “These tactics are lowering, as well as undermining, the perceived value of new product innovations and inventions. We remain hopeful that the defendants will realize the serious impact of such a precedent on the entire life sciences industry, and that they will work with us to properly resolve this issue.”

Date: June 30, 2010
Source: Celsis In Vitro, Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE